

Geert Jan Groeneveld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624402/publications.pdf>

Version: 2024-02-01

105
papers

2,344
citations

279798

23
h-index

254184

43
g-index

113
all docs

113
docs citations

113
times ranked

3159
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1396-1406.	27.0	674
2	Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2009, 66, 227-234.	5.3	111
3	Mitochondrial function is impaired in the skeletal muscle of pre-frail elderly. <i>Scientific Reports</i> , 2018, 8, 8548.	3.3	76
4	EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 5775.	3.3	65
5	Effects on Spasticity and Neuropathic Pain of an Oral Formulation of δ^9 -tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. <i>Clinical Therapeutics</i> , 2018, 40, 1467-1482.	2.5	59
6	Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers. <i>Anesthesiology</i> , 2017, 126, 697-707.	2.5	49
7	<sc>DNL</sc>104, a Centrally Penetrant <sc>RIPK</sc>1 Inhibitor, Inhibits <sc>RIP</sc>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 406-414.	4.7	48
8	The Use of Biomarkers in Human Pharmacology (Phase I) Studies. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 55-74.	9.4	45
9	Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. <i>Drug Discovery Today: Technologies</i> , 2016, 20, 27-34.	4.0	43
10	A <sc>Large-Scale</sc> Full <sc>i>GBA1</i></sc> Gene Screening in Parkinson's Disease in the Netherlands. <i>Movement Disorders</i> , 2020, 35, 1667-1674.	3.9	41
11	A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 903-922.	2.4	37
12	Fentanyl Utility Function. <i>Anesthesiology</i> , 2013, 119, 663-674.	2.5	36
13	Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-blind, Placebo-controlled, Crossover Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1136-1145.	4.7	36
14	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 310-313.	2.4	35
15	Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 301-309.	2.4	34
16	Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects. <i>Clinical and Translational Science</i> , 2020, 13, 318-324.	3.1	32
17	Safety, pharmacokinetics and target engagement of novel <sc>RIPK1</sc> inhibitor <sc>SAR443060</sc> (<sc>DNL747</sc>) for neurodegenerative disorders: Randomized, <sc>placebo-controlled</sc>, <sc>double-blind</sc> phase I/II studies in healthy subjects and patients. <i>Clinical and Translational Science</i> , 2022, 15, 2010-2023.	3.1	31
18	The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 976-990.	2.4	30

#	ARTICLE	IF	CITATIONS
19	The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. <i>Neuromuscular Disorders</i> , 2019, 29, 21-29.	0.6	30
20	Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation. <i>Pharmacological Reviews</i> , 2020, 72, 899-909.	16.0	30
21	A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3561-3573.	2.4	29
22	An Association Study of Riluzole Serum Concentration and Survival and Disease Progression in Patients With ALS. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 718-722.	4.7	26
23	Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. <i>Molecular Pain</i> , 2018, 14, 174480691879704.	2.1	26
24	Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1020-1028.	2.4	25
25	Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson's disease: a comparative study. <i>Journal of Clinical Movement Disorders</i> , 2020, 7, 4.	2.2	24
26	Parametric Binding Images of the TSPO Ligand ¹⁸ F-DPA-714. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1543-1547.	5.0	23
27	Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 637-645.	4.7	22
28	Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1011-1021.	2.4	20
29	Analgesic potential of PF-06372865, an $\hat{1}\pm 2/\hat{1}\pm 3/\hat{1}\pm 5$ subtype-selective GABAA partial agonist, in humans. <i>British Journal of Anaesthesia</i> , 2019, 123, e194-e203.	3.4	20
30	Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 108-117.	2.4	18
31	Responsiveness of electrical nociceptive detection thresholds to capsaicin (8%) -induced changes in nociceptive processing. <i>Experimental Brain Research</i> , 2016, 234, 2505-2514.	1.5	18
32	The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 371-397.	1.8	17
33	Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. <i>PLoS ONE</i> , 2022, 17, e0256752.	2.5	17
34	Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 751-763.	2.4	16
35	Relationships Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence From Patients With Cryptogenic Axonal Polyneuropathy. <i>Diabetes Care</i> , 2017, 40, 583-590.	8.6	16
36	Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 721-731.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Simultaneous tracking of psychophysical detection thresholds and evoked potentials to study nociceptive processing. <i>Behavior Research Methods</i> , 2020, 52, 1617-1628.	4.0	16
38	Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on dropâ€ seizure frequency. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 380-385.	2.4	15
39	First in human study with a prodrug of galantamine: Improved benefitâ€ risk ratio?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 13-22.	3.7	14
40	Effect profile of paracetamol, ð™9â€<scp>THC</scp> and promethazine using an evoked pain test battery in healthy subjects. <i>European Journal of Pain</i> , 2018, 22, 1331-1342.	2.8	14
41	Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?. <i>Pharmacogenomics Journal</i> , 2020, 20, 220-226.	2.0	14
42	Parasitic pharmacology: A plausible mechanism of action for cannabidiol. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 189-191.	2.4	14
43	Modeling buprenorphine reduction of fentanyl-induced respiratory depression. <i>JCI Insight</i> , 2022, 7, .	5.0	14
44	An antiâ€ nicotinic cognitive challenge model using mecamylamine in comparison with the antiâ€ muscarinic cognitive challenge using scopolamine. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1676-1687.	2.4	13
45	Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study. <i>European Journal of Pharmacology</i> , 2017, 815, 290-297.	3.5	13
46	Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized doubleâ€ blind, placeboâ€ controlled crossâ€ over trial. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 697-703.	3.9	13
47	Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 515-528.	4.1	13
48	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. <i>Pain Medicine</i> , 2021, 22, 1814-1826.	1.9	13
49	Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	12
50	Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs. <i>European Journal of Pain</i> , 2019, 23, 1129-1140.	2.8	12
51	Utility of Animal Models to Understand Human Alzheimerâ€™s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3158.	4.1	12
52	The impact of the global COVIDâ€ 19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 837-844.	2.4	12
53	Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 87.	6.2	11
54	Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 139-144.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 888-899.	2.4	10
56	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 10.	6.2	10
57	Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B. <i>Neurotherapeutics</i> , 2020, 17, 1300-1310.	4.4	10
58	First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M ₁ receptor partial agonist for the treatment of dementias. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2945-2955.	2.4	10
59	Alternative trial design in amyotrophic lateral sclerosis saves time and patients. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2007, 8, 266-269.	2.1	9
60	The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects. <i>European Journal of Pain</i> , 2019, 23, 874-883.	2.8	9
61	Safety, pharmacokinetics, and pharmacodynamics of Gln1062, a prodrug of galantamine. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12093.	3.7	9
62	Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies. <i>Medicine in Drug Discovery</i> , 2021, 10, 100083.	4.5	9
63	An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. <i>Clinical Neurophysiology</i> , 2018, 129, 2325-2332.	1.5	8
64	No synergistic effect of subtherapeutic doses of donepezil and EVP6124 in healthy elderly subjects in a scopolamine challenge model. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 89-98.	3.7	8
65	A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning ^{i>Off} of ^{AZ}. <i>Movement Disorders</i> , 2022, 37, 790-798.	3.9	8
66	Predictors of simulated driving performance in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 64-69.	2.2	7
67	Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy. <i>Brain Research</i> , 2020, 1730, 146621.	2.2	7
68	Safety, pharmacokinetics and pharmacodynamics of SBT020 in patients with early stage Huntington's disease, a 2-part study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2290-2302.	2.4	7
69	Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1466-1478.	2.0	7
70	Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2814-2829.	2.4	7
71	No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. <i>European Journal of Pain</i> , 2017, 21, 494-506.	2.8	6
72	Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1615.	4.1	6

#	ARTICLE	IF	CITATIONS
73	Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation. <i>Experimental Brain Research</i> , 2022, 240, 631.	1.5	6
74	Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2926-2937.	2.4	6
75	Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling. <i>Clinical and Translational Science</i> , 2016, 9, 321-327.	3.1	5
76	Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. <i>Journal of Psychopharmacology</i> , 2017, 31, 192-203.	4.0	5
77	Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 33-36.	1.5	5
78	Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 84-90.	2.2	5
79	Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performance. <i>PLoS ONE</i> , 2021, 16, e0260783.	2.5	5
80	Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions. <i>Traffic Injury Prevention</i> , 2018, 19, 708-714.	1.4	4
81	Comparable rates of simulator sickness in Huntington's disease and healthy individuals. <i>Transportation Research Part F: Traffic Psychology and Behaviour</i> , 2019, 60, 499-504.	3.7	4
82	First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR324, a dual enkephalinase inhibitor for pain management. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	4
83	Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects. <i>Drugs in R and D</i> , 2021, 21, 295-304.	2.2	4
84	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 132.	6.2	4
85	A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX128, a highly selective Na ^v 1.8 inhibitor, in healthy adults. <i>Clinical and Translational Science</i> , 2022, 15, 981-993.	3.1	4
86	A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	3
87	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.	1.0	3
88	Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial. <i>JMIR Formative Research</i> , 2021, 5, e31890.	1.4	3
89	Pharmacodynamic Evaluation: Pain Methodologies. , 2018, , 1-31.		2
90	Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 573-580.	2.5	2

#	ARTICLE	IF	CITATIONS
91	Spotlight Commentary: Importance of dose redefining in the process of drug repurposing. British Journal of Clinical Pharmacology, 2021, 87, 1705-1707.	2.4	2
92	False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance. Scientific Reports, 2021, 11, 161.	3.3	2
93	Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innovations in Clinical Neuroscience, 2015, 12, 5S-10S.	0.1	2
94	Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population. Annals of Neurology, 2020, 87, 154-155.	5.3	1
95	Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntington's Disease. Journal of Huntington's Disease, 2020, 9, 335-344.	1.9	1
96	Intronic Haplotypes in <sc>GBA</sc> Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup. Movement Disorders, 2021, 36, 1468-1470.	3.9	1
97	Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1 acetylcholine receptor agonist: A randomized crossover trial. British Journal of Clinical Pharmacology, 2021, 87, 4439-4449.	2.4	1
98	Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clinical and Translational Science, 2022, 15, 638-648.	3.1	1
99	Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clinical Pharmacology and Therapeutics, 2022, 112, 1008-1019.	4.7	1
100	P1-368: EFFECT ON MEMORY AND ATTENTION OF TWO DOSES OF MEMOGAIN, A PRODRUG OF GALANTAMINE, IN HEALTHY SUBJECTS. , 2014, 10, P449-P450.		0
101	19th biennial IPEG Meeting. Neuropsychiatric Electrophysiology, 2016, 2, .	4.1	0
102	P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.8	0
103	H56...Driving performance of huntington's disease gene carriers. , 2018, , .		0
104	Pharmacodynamic Evaluation: Pain Methodologies. , 2020, , 95-125.		0
105	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	0